Two Phase III biotechs will join the Nas­daq Fri­day morn­ing, with ra­dio­phar­ma start­up Rayze­Bio and brain dis­ease drug de­vel­op­er Neumo­ra pric­ing their IPOs at $311 mil­lion and $250 mil­lion, re­spec­tive­ly.
Rayze­Bio and Neumo­ra wooed in­vestors dur­ing a rel­a­tive­ly icy IPO mar­ket, which is be­gin­ning to thaw as oth­er biotech star­tups are lin­ing up to…